Replies to post #166692 on Biotech Values

[DewDiligence]

GSK/THRX—Relvar Ellipta approved for asthma in Japan:

http://finance.yahoo.com/news/relvar-tm-ellipta-tm-gains-070000827.html

See #msg-92194902 for background. I don’t know why application wasn’t reviewed for COPD in Japan.

[DewDiligence]

GSK/THRX—The CHMP today approved Revinty Ellipta (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002044.jsp&mid=WC0b01ac058004d5c1 ), which appears to be the same product (or a minor reformulation) as Relvar Ellipta, which was endorsed by the CHMP in Oct 2013 (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002673/smops/Positive/human_smop_000591.jsp&mid=WC0b01ac058001d127 ). If anyone understands the distinction here, please post.